CompanyHealthAi
Totus Medicines
Totus Medicines is a clinical-stage precision medicines company in Emeryville, California, building covalent small-molecule drugs against historically undruggable targets. Its AI-powered OmniDEL platform screens billions of DNA-encoded covalent candidates against thousands of targets inside living cells, surfacing molecules that older methods miss. Its lead program, TOS-358, is the first and only covalent PI3Ka inhibitor in clinical development, showing class-leading tolerability and strong disease control in breast, endometrial, and head & neck cancers.
2019Founded
EmeryvilleHQ
~$41M (part of $107M total)Earlier rounds (Seed/Series A)
biotechdrug-discoverycovalent-inhibitorsoncologyai-drug-designsmall-molecules